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Abstract 
 
Introduction  
Esophageal cancer has a poor prognosis. Multimodality approach with neoadjuvant 
chemoirradiation followed by surgery is the treatment of choice. For patients who are 
inoperable or refusing surgery, definitive chemoirradiation is the standard modality of 
treatment. At present, the survival rates of esophageal cancer are low and improving 
the quality of life is one of the aims of treatment. Dysphagia due to radiation induced 
stricture is one of the distressing complications of definitive radiation therapy in 
esophageal cancer patients which decreases the quality of life. This study addresses the 
incidence and risk factors for the development of strictures following radiation therapy 
and attempts to predict the formation of the same, which in turn may aid in selection of 
the best modality of treatment. 
Aim 
The study aims to find the incidence of esophageal stenosis and risk factors causing the 
stenosis following definitive radiation therapy. It also aims to formulize an equation for 
the prediction of esophageal stenosis based on the identified risk factors. 
Methodology 
This is both a prospective and retrospective observational study which included the data 
of esophageal cancer patients from January 2008 to July 2013. The study included 100 
patients with locally advanced esophageal cancer who underwent definitive radiation 
therapy with or without chemotherapy. Esophageal stenosis was evaluated during the 
first follow up and three monthly thereafter by endoscope negotiability. This study 
investigated the correlation between esophageal stenosis after radiation therapy and 
risk factors related to tumour and treatment characteristics. For validation of the 
correlative factors for esophageal stenosis, boot strapping method was employed. A 
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formula was then derived to predict the esophageal stenosis following definitive 
radiation therapy. 
Results 
Out of the 100 patients, data for 72 patients, who came for follow up, were available for 
analysis. The incidence of stenosis after definitive radiation therapy was 43 % (31 out of 
72 patients). On univariate analysis, esophageal stenosis was likely to occur if the 
patient had T4 stage of esophageal cancer, the endoscope not being negotiable prior to 
radiation therapy, and involvement of the entire circumference of esophageal wall. In 
multivariate analysis, T4 stage alone correlated significantly with stenosis of esophagus 
(p= 0.03). Bootstrapping analysis showed that T4 stage and the extent of circumference 
of esophageal wall involved were significant factors for predicting stenosis (OR -1.90 and 
5.18 respectively). A derivational formula was thus arrived at to predict the esophageal 
stenosis.    
Prediction equation = y
y
e
e
+1  , where  
 = -4.1435+0.6356*staging-0.4674*scopnego+0.5340*length-0.0965*wallthick + 
1.6455*circumference.  
 
Conclusions 
Our study suggests that T4 stage and the involvement of full circumference of the 
esophageal wall are significant risk factors for formation of esophageal stenosis 
following radiation therapy. The predictive formula which was derived from the 
derivative  cohort needs to be validated prospectively in a larger sample of patients. 
Keywords: Esophageal stenosis, Definitive radiation therapy, Esophageal Cancer 
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Aim of the Study 
 
1. To find the incidence of esophageal stenosis  after definitive radiation therapy 
2. To identify the risk factors associated with the development of esophageal 
stenosis after definitive radiation therapy. 
3. To formulize an equation for prediction of esophageal stenosis based on the 
identified risk factors. 
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Introduction 
 
Esophageal cancer is the eighth most common cancer worldwide. It is more common in 
males, with male to female ratio of 3-5:1. The main symptoms with which esophageal 
cancer patients present with are dysphagia, weight loss, heart burn, odynophagia and 
shortness of breath. Of these symptoms, dysphagia is the main symptom responsible for 
decreasing the quality of life. The mortality rate among the esophageal cancer patients 
despite radical treatment is high. The two and five year overall survival rates are 24.3 % 
and 13.8 % respectively(1). As the overall survival rates in esophageal cancer patients 
are low, one of the main intent of treatment in these patients is improving the quality of 
life.  
Esophageal cancer patients can be treated by surgery or non surgical techniques 
depending on the stage. Patients with early stage esophageal cancer, T1 and T2 lesions 
are best treated with surgery. Stages I to III, selected IVA are considered for curative 
resection, while IVB tumours are considered unresectable. Those tumours with doubtful 
invasion into the surrounding structures and those tumours which cannot get adequate 
margins after surgery are considered for neoadjuvant chemoirradiation followed by 
surgical excision. Those with locally advanced disease and who are considered 
unsuitable for surgery due to comorbid conditions are offered definitive 
chemoirradiation. Even with the combined modality treatment approaches, overall 
survival rates continue to be dismal.  The mortality rates are high within the first two 
years(2). Although surgery has been the main modality of treatment, there is however, 
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no compelling evidence to show that survival rates are better in surgery group than in 
the definitive radiation therapy group (3). 
As the survival rates are low with the available treatment modalities, improvement of 
quality of life remains to be one of the main aims of treatment. Definitive 
chemoirradiation is the option for patients who are considered unresectable or in those 
patients who refused surgery. Definitive chemoirradiation comprises of 45 Gy of 
external beam irradiation along with concurrent chemotherapy over a period of 5 weeks 
followed by two fractions of intraluminal high dose rate brachytherapy. The main 
complication of radical chemoirradiation is early esophageal stenosis, which is 
multifactorial either due to fibrosis or tumour regression. Esophageal stenosis reduces 
the quality of life in patients receiving radical radiation therapy.  The causative factors 
responsible for esophageal stenosis after definitive chemoirradiation are  higher tumour 
(T) stage (TNM classification), length of the esophagus involved, extent of involved 
circumference and also the wall thickness of esophagus at the time of treatment(4).  
The quality of swallowing had been assessed in operable esophageal cancer patients 
who underwent surgery or definitive radiation therapy(5). This showed that surgery 
resulted in improvement of swallowing twice as much as in patients who received 
radiation therapy after correction for time and pretreatment swallowing status. 
Predicting esophageal stenosis prior to radiation therapy may aid the patient in 
selecting the treatment modality which may result in a lower risk of esophageal 
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stenosis, especially in a patient suitable for surgery, but is not keen to undergo surgery 
(5).  
The proposed study is both a retrospective and prospective study, which assesses the 
stenosis after radiation therapy objectively with endoscopy and imaging modalities and 
correlates the same with the patient’s symptoms. It will assess the patient’s symptoms 
before and after radiation therapy and correlate the dysphagia with the risk factors. By 
knowing the risk factors prior to radiation therapy it is possible to select patients who 
will not develop symptomatic esophageal stenosis after radiation therapy. 
There are limited studies for evaluating the frequency and severity of esophageal 
stenosis after radical chemoirradiation in esophageal cancer patients. This study will 
attempt to validate the risk factors which are causing esophageal stenosis and 
predicting the severity of stenosis caused because of tumour regression and radiation 
therapy based on those risk factors. 
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Literature review  
Epidemiology 
 
Oesophageal cancer is the eighth most common cause of cancer in the world accounting 
for   3.8 % of total estimated cancers in 2008. It is the sixth most common cause of 
death accounting for 5.4 % of total cancer patient deaths. Esophageal cancer is more 
common in males than females with male to female ratio of 3 to 5:1.  In 2008, new 
esophageal cancer cases identified were 4, 82,300 and number of deaths which 
occurred due to esophageal cancer were 4, 06,800 globally.  Highest rates were found in 
Southern and Eastern Africa and Eastern Asia. The highest risk area stretches from the 
northern Iran along the Central Asian republic to North-Central China. This is referred as 
esophageal cancer belt in which 90% of the cases are squamous cell carcinomas. Major 
risk factors for the high incidence of esophageal cancer in this belt are not clearly 
known. However, poor nutrition, drinking beverages at high temperatures, low intake of 
fruits are considered risk factors. Lower incidence is seen in United States and many 
Western countries. In Westren countries there is increased incidence of esophageal 
adenocarcinoma, which rose to greater than 300 to 500 % in the last 30 to 40 year 
period (6,7). However, the etiology of 90 % squamous cell carcinoma of esophagus in 
these countries constitutes smoking and alcohol (8).  
In India, incidence of esophageal cancer is moderately high. It is the fourth most 
common cancer among the males and ranks fifth among the females. According to the 
Indian population based cancer registries, the incidence of oesophageal cancer was 
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42,447 in 2001 and is projected to increase to 66,672 by 2016 (2).  In India the estimated 
number of patients having esophageal cancer in the previous 5 years was 2,57,000 from 
2008.  According to International agency of research on cancer, India had 47,000 cases 
per year in 2008 and mortality of 42,000 patients per year (9).  
According to Cancer Registry of Chennai, from 2006 to 2008, the incidence of 
esophageal cancer among males was 6.8 % and among females was 3.45 %. The crude 
rate of incidence of esophageal cancers per 1,00,000 population was 6.8 % among the 
males and 3.9 % among the female population. The age adjusted average annual 
incidence of esophageal cancer was 7.6 % among the males and 4.3 % among females. 
The mortality rate of esophageal cancer from 2006 to 2008 was 6.92 % among the male 
population and 4.9 % among the female population.(10) 
There are variations in the incidence of esophageal cancer according to histological 
subtypes. Incidence of adenocarcinoma of esophagus is mostly seen in Western 
countries due to obesity. The percentage of adults who are overweight has been 
increased in the population to greater than 33 %. The mechanism by which obesity 
predisposes to esophageal adenocarcinoma may be increased intraabdominal pressure 
and increased risk of of gastroesophageal reflux disease and progression to metaplasia 
of Barrett’s esophagus(6). However, these countries have a reduced incidence of 
squamous cell carcinoma due to reduction in tobacco and alcohol consumption. Asian 
countries have higher incidence of squamous cell carcinomas of esophagus due to 
increased tobacco and alcohol consumption.(11) 
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Oesophageal Cancer Incidence and Mortality Worldwide in 2008 
Summary : GLOBOCAN 2008 
 
Gross anatomy  
 
The oesophagus is a muscular tube like organ starting from C6 vertebra after 
hypopharynx and extending to T11 region into stomach.  It starts from the 
cricopharyngeus muscle till the gastro-esophageal junction.  It is divided into cervical 
and thoracic esophagus. The thoracic esophagus is in turn divided into three parts: 
Trends in incidence of oesophageal 
cancer in selected countries: age-
standardised rate (W) per 100,000, 
women 
Trends in incidence of oesophageal 
cancer in selected countries: age-
standardised rate (W) per 100,000, men 
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upper, middle and lower third esophagus which is divided based on specific anatomical 
boundaries. 
 
 
 
The length of the esophagus extends from 22 – 30 cm and it varies according to the age 
and gender.  The cricopharyngeal region is around 14 to 15 cm from the incisor teeth 
and the gastroesophageal junction is 38 to 42 cm from the incisor teeth.  The cervical 
Anatomical division of Esophagus. In: AJCC Cancer Staging Manual, 7 th 
edition, 2010. 
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esophagus extends from 16 to 20 cm, i.e from cricopharyngeus muscle to thoracic inlet. 
The upper third esophagus extends from 20 to 25 cm, i.e from thoracic inlet to tracheal 
bifurcation. The middle third esophagus extends from 25 to 32 cm and lower third 
esophagus extends from 32 to 40 cm.  The anatomical regions are important in decision 
making of treatment of esophageal cancer.(12) 
Staging of esophageal cancer 
 
The American Joint Committee on Cancer had proposed the TNM classification of 
carcinoma of esophagus.  The staging is as follows according to the AJCC 7 th edition, 
2010 : 
Primary Tumor (T) 
TX: Primary tumor cannot be assessed 
T0: No evidence of primary tumor 
Tis: High-grade dysplasia** 
T1: Tumor invades lamina propria or submucosa 
T1a: Invasion of lamina propria or muscularis mucosa 
T1b: Invasion of submucosa 
T2: Tumor invades muscularis propria 
T3: Tumor invades adventitia 
T4: Tumor invades adjacent structures 
T4a: Resectable tumor invading pleura, pericardium, or diaphragm 
T4b:Unresectable tumor invading other adjacent structures such as aorta, vertebral 
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body, trachea etc. 
*At least maximal dimension of tumor must be recorded; multiple tumors require the 
T(m) suffix. 
**High-grade dysplasia includes all noninvasive neoplastic epithelia that was formerly 
called carcinoma in situ, a diagnosis that is no longer used for columnar mucosa 
anywhere 
in the gastrointestinal tract. 
Regional Lymph Nodes (N) 
NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Metastasis in 1-2 regional lymph nodes 
N2: Metastasis in 3-6 regional lymph nodes 
N3: Metastasis in seven or more regional lymph nodes 
*Number must be recorded for total number of regional nodes sampled and total 
number of reported nodes with metastasis 
Distant metastasis (M) 
MX: distant metastasis cannot be assessed 
M0: no distant metastasis 
M1: distant metastasis 
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Physiology of swallowing 
 
Swallowing or deglutition is act of swallowing, through which a food bolus is 
transported from the mouth through pharynx and esophagus into the stomach.  
Swallowing is divided into three phases, namely:  
1. Oral  
2. Pharyngeal  
3. Esophageal  
Of these three phases, the esophageal and pharyngeal phases of swallowing are vital to 
understand the effects of radiation on swallowing.  
Pharyngeal phase: 
The steps involved in pharyngeal phase of swallowing are: 
1. Elevation of the soft palate to contact posterior pharyngeal wall preventing the 
regurgitation of food bolus into nasopharynx. This is also called velopharyngeal 
valving 
2. Elevation of the larynx and hyoid bone towards the base of tongue causing 
flipping of epiglottis to cover glottis. 
3. Pharyngeal muscle constriction from above to downward direction 
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4. Relaxation of the cricopharyngeal sphincter to allow the passage of food bolus 
into esophagus 
 
The soft palate is elevated by the levator veli palatine muscles so that it comes in 
contact with the posterior pharyngeal wall and prevents the food from coming into the 
nose during swallowing.  
During swallowing the important action is adduction of the vocal cord to protect the 
tracheal airway. This action occurs before the elevation of larynx and hyoid. After the 
adduction of true vocal cords, false vocal cords, aryepiglottic folds adduct and finally 
flipping of epiglottis to cover the glottis. 
The epiglottis also helps in rolling of food bolus to pyriform sinuses. These areas are 
places where residual food bolus may accumulate and may result in aspiration.  There 
will be a time period when no breathing happens during swallowing; however 
swallowing tends to occur in expiration. 
Pharyngeal peristalsis takes place when true vocal cords adduct and this is evidenced by 
contraction of the pharyngeal constrictor muscles in superior-inferior order. When the 
superior constrictor is contracted, the larynx begins to elevate.  
The food bolus then reaches the cervical region of esophagus.  
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Esophageal phase: 
This phase starts when the bolus enters the esophagus. The bolus is carried through 
peristaltic movement until the lower esophageal sphincter. The lower esophageal 
sphincter opens to allow bolus into the stomach. The peristaltic movement requires the 
action of esophageal musculature. It creates a positive pressure in esophageal chamber 
to move bolus towards stomach.  The lower esophageal sphincter closes once the food 
enters the stomach and cannot move back up into the esophagus. 
Symptoms in Esophageal cancer patients 
 
The five most frequent symptoms associated with esophageal cancer are dysphagia 
(74%), weight loss (57.3%), heart burn (20.5 %) odynophagia (16.6 %) and shortness of 
breath (12.1 %). The most common presenting symptom is esophageal cancer patients is 
dysphagia. Other symptoms and signs associated with esophageal cancer are cervical 
lymphadenopathy, chronic cough, hematemesis, hemoptysis, hoarseness of voice. 
Dysphagia is associated with other symptoms as a combination in 8 out of 10 patients.  
The most common combination of symptoms associated with dysphagia is weight loss.  
This is associated with poor quality of life of patient as well as it is  a poor prognostic 
factor.(13) 
Dysphagia is difficulty in having initiation of swallowing or a feeling that liquid or solid 
diet is getting obstructed in the passage from mouth to stomach. It is a perception of 
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that there is a hindrance in normal passage of food.  Dysphagia can be due to 
oropharyngeal causes or due to esophageal causes. 
  Patients with esophageal cancers have varied range of swallowing difficulty from solids 
to liquids. However, most patients have difficulty in swallowing solids but not to liquids 
which is due to the mechanical obstruction with luminal narrowing to diameter less than 
15 mm (3).  If the esophageal cancer is left untreated, symptoms would progress causing 
absolute dysphagia.  This causes marked weight loss because of poor intake.  All these 
symptoms causes decrease in quality of life of patient. 
Locally advanced esophageal cancer has poor prognosis and have 5 year survival rates of 
approximately 20 – 30 %. As the survival rates are poor, the primary aim of treatment in 
esophageal cancer patients is to improve the symptoms and quality of life along with 
intention to cure. Of all the symptoms, dysphagia need to be addressed with importance 
as it is the major contributing factor of decreasing the quality of life of patients. 
 
Factors causing esophageal stenosis after radiation therapy 
 
As briefly mentioned earlier, various factors play a role in causing stenosis after 
definitive chemoirradiation. 
Very few studies were done which correlated esophageal stenosis with specific factors. 
Of the various factors, the important factors which were studied were age, gender, 
tumour stage, circumference of the esophagus involved, length of the tumour, wall 
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thickness of the tumour, site of the esophagus involved, dysphagia score before 
initiation of the treatment, stenotic level before the treatment, dose of radiation 
therapy, whether intraluminal radiation therapy was a component of the radiation 
course and whether concurrent chemotherapy was administered(4,14).  
Age of the patient was not correlated with the esophageal stenosis. Studies were done 
where they had categorized patients either as above and below 60 years or above and 
below 70 years. But, they were not predictive of increased rates of stenosis in either 
group. 
Male or female patients had same rate of stenosis rates and were only dependent on 
other factors. Gender had no significant correlation with esophageal stenosis after 
radiation therapy. However studies predicting esophageal stenosis after radiation 
therapy to head and neck cancers showed that females have more predilection to form 
stenosis(15). 
Various stages of Esophageal Cancer (staged according to AJCC) have been correlated 
with esophageal stenosis after radiation therapy. The correlation of tumour stage and 
stenotic rates has been variable in literature. Some studies showed a significant increase 
in the rate of stenosis in higher stages i.e T4 whereas T2 and T3 tumours had stenotic 
rates almost half the rate of the T4 stage tumours(4). However, some studies have 
shown no difference in esophageal stenosis rates after definitive radiation therapy 
across various T stages. 
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Circumference of the esophagus involved at the time of diagnosis has a high degree of 
correlation with the esophageal stenosis after radiation therapy. It was studied whether 
or not whole circumference of esophagus was involved. Full circumference involvement 
of esophagus by the tumour was highly predictive of esophageal stenosis after radiation 
therapy.(4,16) 
Length of the tumour in esophageal cancer at the time of diagnosis was studied for the 
prediction of esophageal stenosis. In some studies it was grouped into those greater 
than 5 cm and those less than 5 cm where as in others, it was grouped into greater than 
8 cm or less than 8 cm. The results however were contradictory. Retrospective studies 
done by Atsumi et al which were analyzed by univariate and multivariate analysis 
showed variable results. In one of the studies, length of esophageal involvement by the 
tumour which was greater than 5 cm had correlation with esophageal stenosis after 
radiation therapy (p = 0.005) (16). A randomized trial showed 99 operable esophageal 
cancer patients were randomly allocated into surgery arm and radiotherapy arm based 
on age, T stage and length of esophageal involvement whether less than or greater than 
5 cm and the quality of life was assessed which showed no significant difference either 
groups (5). 
Esophageal wall thickness of the tumour region was strongly correlated with formation 
of stenosis after completion of radiation therapy. The patients were divided into 
subgroups of those having wall thickness of 1 cm and less and those with wall thickness 
greater than 1 cm. The latter group had significant increase in the incidence of 
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esophageal stenosis as compared with former group. The wall thickness of 1 cm and less 
had 0 to 2 % stenotic rates as compared to 32- 38 % in those having wall thickness of 
greater than 1 cm(4,16). 
Site of involvement of esophageal cancer was not critically evaluated as factor for 
prediction of esophageal stenosis following definitive radiotherapy. Most of the studies 
done on esophageal cancer and radiation therapy involved middle third of esophagus. 
Study done by Khurana et al in 2007,  showed no difference in the stenotic rates 
between upper, middle or lower third esophagus (14). 
Dysphagia score at the initiation of treatment correlated with the severity of stenosis at 
the time of presentation. Dysphagia was scored based on the diet which the patient was 
able to eat i.e.  whether patient could eat solid diet, soft & pureed food, liquid diet or 
nothing at all. The results were varied in various studies. The dysphagia grade did not 
correlate with the stenosis formation after radiation therapy. But the grade of stenosis 
before starting treatment had predicted the formation of stricture after radiation. The 
esophageal stenosis was grouped according to those who are having greater than 50 % 
lumen stenosed or those having less than 50 % of the lumen stenosed. Esophageal 
stricture formation was higher with patients having stenosis causing greater than 50 % 
of the lumen compromise before the initiation of the treatment (4). 
Studies which correlated various dose regimens given as external beam radiation 
therapy to formation of esophageal stenosis were not significant. Study done by Atsumi 
et al had categorized patients into those who received dose less than or greater than 65 
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Gy, which did not show any difference in stenosis formation. However, in the next study 
he divided patients into those who received radiation dose greater than 65 Gy to the 
tumour bed and those receiving between 65 to 70 Gy and those who received greater 
than 70 Gy. In this study he showed those patients who received greater 70 Gy had 
higher stenotic rate formation after completion of the treatment (13 vs 13 vs 33 %) (16).  
However no specific dose limits for esophagus could be illustrated due to lack of 
published data. It is suggested from clinical data that 74 Gy could be safely administered 
to a segment of esophagus with concurrent chemotherapy (17).  
Intraluminal brachytherapy (ILRT) following external beam radiation therapy is an 
important contributor for esophageal stenosis formation. It depends upon various 
factors like duration between ILRT and external beam radiation therapy, type of 
applicator used, dose fractionation, interval between two ILRT doses and total dose 
given. Stenotic rates were higher if the duration between external beam irradiation and 
ILRT was less than one week. If applicators of lesser than 1 cm in diameter is introduced 
for ILRT it causes higher rates of injury to esophagus and there by higher stenotic rates. 
If the applicator diameter was less than 2 mm the complication rates were 24 % as 
compared to 19 % with diameters of 2 to 6 mm and 5 % with those applicators having 
diameter greater than 6 mm.  Those receiving less than 5 Gy had complication rate of 
9.5 %, those receiving between 5 to 8 Gy had complication rate of 20 % and those 
receiving greater than 8 Gy had complication rates of 38 %. It was suggested that 
smaller fraction size should be used as far as possible with the total dose received by 
ILRT keeping at 10 to 12 Gy. (18). Shorter interfraction intervals of three to seven days 
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causes higher rates of stricture formation as compared to those greater than one week 
gap between the two fractions (14).  The time to the formation of stricture after 
intraluminal radiation therapy was lesser when compared with those who received 
external beam radiation alone.  
Concurrent chemotherapy when given along with radiation therapy was associated with 
higher incidence of stenotic formation after definitive chemoirradiation. Various 
chemotherapy regimens like weekly Cisplatin, 2 cycles of Cisplatin and 5 Flourouracil, 2 
cycles of 5 –Flourouracil and Mitomycin, weekly Docetaxel, weekly Paclitaxel and 
Carboplatin have been tried as concurrent chemoirradiation. Concurrent chemotherapy 
when administered along with radiation therapy had higher incidence of stricture 
formation than those who did not receive     ( 12 % in historical group vs 34 % in those 
who received chemoirradiation and ILRT) (14).   Those who received both ILRT and 
concurrent chemotherapy with external beam radiation therapy had higher incidence of 
stricture formation than those who received external beam radiation and ILRT alone. 
The hazard ratio was 4.2 in concurrent chemoirradiation group as compared with those 
who did not receive chemotherapy. It was suggested that ILRT should be used with 
caution in those patients who are receiving chemotherapy. 
With these factors as background which can affect the outcomes and complications 
after treatment of esophageal cancer, the present study concentrates on specific factors 
which will be dealt in detail in materials and methods section. 
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Patho-physiology of radiation induced esophageal strictures  
 
The detailed mechanism by which esophageal stenosis occurs after radiation therapy 
are not known.  However, fibrosis or ischemia occurring during radiation therapy are the 
main identified factors contributing to stenosis. The above mechanisms can happen 
during the tumour shrinkage also. Studies have shown that esophageal stenosis after 
radiation therapy to the neck and thorax region showed histological evidence of fibrosis 
of the sub-mucosa and hyalinization of the smooth muscle layers of the esophagus.  This 
is followed by accumulation of macrophages which releases pro-inflammatory 
cytokines.(19) This causes thickening in the submucosa and muscular layers causing 
edema and fibrosis. The vascular damage and ischemia associated with esophageal 
stenosis after radiation therapy is less important. These processes occur more around 
the tumours which shrink and respond to radiation therapy.  Esophageal stricture is a 
result of scarring or due to abnormal growth in the esophageal lumen. The involved 
circumference of esophagus shows greater co-relation with effects radiation therapy 
due to the above mechanisms explained.  Similar process has been observed in patients 
who had undergone esophageal mucosal resection. Esophageal cancer patients who had 
underwent esophageal mucosal resection had a higher propensity for esophageal 
stenosis if two thirds to three fourths of the circumference of the esophageal mucosa 
was removed (16).   
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In order to predict the risk factors, the patho-physiology of radiation induced 
esophageal stenosis is important. Circumference of esophagus wall involved and the 
wall thickness might help in prediction of esophageal stenosis following definitive 
chemoirradiation. 
 
Treatment protocols for esophageal cancer and the complications 
associated with them 
 
Survival rates of esophageal cancer have remained low; however the outcomes of the 
resectable loco-regional disease have improved with multimodality treatment, which 
include radiation, chemotherapy and surgery.  The symptoms associated with 
esophageal cancer occur when the disease is fairly advanced.  Most of the patients are 
therefore diagnosed at late stages (3). As there is a paucity of large randomized trials, 
treatment decisions are based on either small randomized trials or meta-analyses. 
Treatment of esophageal cancers is one the difficult challenges for surgeons, radiation 
oncologists and medical oncologists.  
For early esophageal cancer patients with stages cT1 – T2 N0 disease, surgery alone 
remains the standard of care for this local disease. There is little evidence which 
supports the use of radiation or chemoirradiation as definitive treatment in patients 
with T1N0 disease. A small study which treated patients who refused surgery into 
external beam radiation therapy alone (64 Gy)  or external beam (52 Gy)  followed by 8 
to 12 Gy of brachytherapy. The 5 year survival rates were 59 %.  However, patients with 
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T2N0 stage, require adjuvant radiation therapy after radical esophagectomy as they 
have 50 % propensity for lymph node metastases (20,21).  
There is controversy for current standard of care for patients with locally advanced 
esophageal cancer (cT3-T4 and or N positive). Until 1980s, surgical resection was the 
main modality of treatment. In 1980s, perioperative chemotherapy, postoperative 
chemoirradiation and preoperative chemoirradiation have found to improve the 
outcomes. These studies had  limitations like inadequate power, type of chemotherapy 
used, dose of chemotherapy, radiation dose and fractionation, radiation delivery 
schedules, initial staging and histological subtypes (22).  
Various queries still persist about the benefits of neoadjuvant radiation, peri-operative 
chemotherapy, concurrent chemoirradiation, surgery and neoadjuvant 
chemoirradiation followed by surgery and also on adjuvant treatment after surgery. The 
ideal treatment for esophageal malignancy is still not defined. 
Phase III studies which have evaluated neoadjuvant radiation showed improved 5 year 
overall survival rates but these were not statistically significant. The use of radiation as 
single modality in neoadjuvant setting for esophageal cancer is not supported by current 
literature (23).  
Phase III trials comparing surgery alone with neoadjuvant chemotherapy alone have 
shown a survival advantage. Medical Research Council trial is the largest one which 
showed 5 year overall survival advantage of 6 % in esophageal adenocarcinoma and 
squamous cell carcinoma. MAGIC trial and the French Cooperative Group had 
30 
 
demonstrated 5 year overall survival advantage of 13 % and 14 % which consisted 
predominately gastric cancer patients. As subsequent studies had shown neoadjuvant 
chemoirradiation to be superior in esophageal cancer, the use of preoperative 
chemotherapy has diminished. 
Chemoirradiation is used both in neoadjuvant setting for esophageal cancer patients or 
in the adjuvant setting for patients with gastro-esophageal junction tumours. It may be 
used as definitive treatment in patients who are not fit for surgery. These decisions 
should ideally be made in a multidisciplinary tumour board setting. RTOG-85-01 trial 
evaluated definitive treatment in patients with esophageal squamous cell carcinoma 
who were not surgically fit. It showed a 5 year over all survival of 27 % in patients who 
received chemoirradiation as compared to 0 % with radiation alone. But the 
locoregional failure was 47 %(24). INT 0123 trial addressed the issue of optimum dose of 
radiation. It randomized patients to high dose (68.4 Gy) or low dose radiation (50.4 Gy) 
and it failed to show that a high radiation dose has an increase in local control or 
survival benefit. 
FFCD 9201 study randomized patients into definitive chemoirradiation and those with 
neoadjuvant chemoirradiation followed by surgery. This showed that patients who 
underwent neoadjuvant chemoirradiation followed by surgery had low rates of local 
recurrence (24 %) as compared to chemoirradiation alone (46 %), however overall 
survival rates at 2 and 5 years did not show statistical difference. The patients who 
underwent surgery had lesser need for palliative treatment for dysphagia as compared 
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to patients who underwent chemoirradiation alone. Study conducted by Stahl et al in 
2005, which compared definitive chemoirradiation and neoadjuvant chemoirradaition 
followed by surgery, showed no difference in the overall survival in both groups, but 
there was improved locoregional control in the patient who underwent surgery. This 
study showed that patients who had clinical tumour response after neoadjuvant 
treatment showed to have improved overall survival.(2,25,26)  The CROSS study which 
randomized operable esophageal cancer patients to surgery alone and preoperative 
chemoirradiation followed by surgery which showed statistically significant improved 
overall survival in the later group (27). Based on these studies, combined modality with 
chemoirradiation and surgery has now become the standard of care as it improved 
locoregional control. 
Many centers use intraluminal brachytherapy in addition to the external beam radiation 
to escalate the radiation dose in a select group of patients. In ILRT, esophagus is 
accessed by a catheter based system and radiation source is used to treat esophageal 
tumours while sparing the normal surrounding structures. ABS guidelines recommends 
intraluminal brachytherapy in treatment of esophagus in two settings; a) as definitive 
treatment in esophageal cancer where there is mucosal involvement of esophageal 
mucosal wall only  and b) as palliative intent in those patients whose life expectancy is 
less than 6 months. It divides the patients into good candidates, poor candidates and in 
those whom ILRT is contraindicated. Good candidates are those in whom the tumours 
are less than 10 cm in length, tumours confined to esophageal wall only, thoracic 
esophagus involvement and no lymphadenopathy. Poor candidates are those with 
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tumours involving more 10 cm of the esophageal length, peri-esophageal extension, 
tumour involving gastroesophageal junction or cardia and positive lymphadenopathy. 
Patients in whom ILRT is contraindicated are presence of esophageal fistula, cervical 
esophageal involvement and in those patients who are having stenosis of esophagus 
which cannot be bypassed (28). There are two types of brachytherapy a) High Dose Rate 
(HDR brachytherapy in which the dose rates are above 12 Gy per hour and b) Low Dose 
Rate (LDR) brachytherapy in which dose rates are below 2 Gy per hour. Various dose 
schedules have been in tried in both HDR and LDR brachytherapy. The RTOG 92-07 study 
showed that survival did not improve with addition of intraluminal brachytherapy to 
definitive chemoirradiation with increase in treatment related fistulas in brachytherapy 
group. It expresses an extreme caution while giving ILRT following external beam 
irradiation(29,30).  Although various schedules have been tried, ABS recommends HDR 
brachytherapy dose as 10 Gy in 2 fractions, 1-2 weeks after completion of external 
beam irradiation, one week apart and LDR dose as 20 Gy given 2-3 weeks after 
completion of the EBRT.  The coverage volume is 1-2 cm proximal and distal to primary 
tumour and the dose prescribed to 1 cm from the source(28). Two prospective studies 
showed improved survival when EBRT was combined with ILRT as compared with EBRT 
alone.  Sur et al randomized patients who are treated with 35 Gy/15 #/ 3 weeks to 
group A who received EBRT dose of 20 Gy/10 #/2 weeks and group B who received ILRT 
dose of 12 Gy/2 sessions/2weeks. They found that group B had higher actuarial survival 
rates (44% in group A vs 78 % in group B) and relief of dysphagia at the end of one year 
(37.5% in group A vs 70.6% in group B) (31).  Several retrospective studies have shown 
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benefit of local control. Although survival did not improve as compared with EBRT alone 
groups, the local control and survival were found to be strongly correlated (32). But the 
largest study was done in Japan with esophageal brachytherapy which randomized 
patients to EBRT and HDR brachytherapy and EBRT alone showed improvement in 2 
year local control rate with no improvement in survival (33). There is clear evidence to 
say that ILRT increases the risk of late complications (esophageal stenosis, broncho-
esophageal fistulas).  However, a retrospective trial conducted by Khurana et al showed 
that there was a threefold increase in late complications following ILRT. Only large 
prospective clinical trials needs to address the benefit of adding brachytherapy boost to 
external beam irradiation of esophageal cancer. 
Surgery plays an important role in treatment of patients with esophageal cancer. Earlier 
studies showed that non-surgical approach was not associated with good results and 
that surgical approaches had better survival rates but with high rates of complications.  
There are three approaches for esophagectomy : a) transhiatal b)transthoracic and c) 
enbloc or radical. Two meta-analyses done in 2001 and 2011 showed no difference in 
survival comparing transhiatal and transthoracic approaches (34,35). In the present era, 
different studies showed the rate of mortality close to zero in patients with non – 
advanced or even advanced tumours. Patients with potentially resectable tumour have 
lower survival rates if not undergoing surgery. The survival of the patient after surgery 
depends on many factors like initial disease status, neoadjuvant and adjuvant treatment 
received and does not depend on surgery alone. 
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 This raises the question whether patients benefit from neoadjuvant chemoirradiation. 
Numerous studies were done with various doses and fraction sizes of radiation, variety 
of chemotherapy regimens and timing of chemotherapy and radiation. Of which 3 
studies had shown benefit with neoadjuvant concurrent chemoirradiation. The CALGB 
9781 trial which randomized patients to cisplatin and infusional 5 Flourouracil with 
concurrent radiation and surgery to surgery alone showed an five year overall survival of 
39 % in combined modality as compared to 16 % with surgery alone. Similar study by 
Walsh et al showed 3 year overall survival of 32 % in multimodality treatment and 6 % in 
surgery alone arm.  Two meta-analyses showed a statistically significant benefit with 
neoadjuvant chemoirradiation when compared to surgery alone (36). The CROSS study 
which randomized operable esophageal cancer patients to surgery alone and 
preoperative chemoirradiation followed by surgery which showed statistically significant 
improved overall survival in the later group (27).  The POET trial which randomized 
patients to chemoirradiation and surgery or chemotherapy and surgery showed that 
neoadjuvant chemoirradiation improved 3 year survival rate from 27.7 % to 47.4 %. 
FFCD 9102 trial AND German Oesophageal Cancer Study Group showed that patients 
with squamous cell carcinoma of esophagus who are treated with chemoirradiation and 
achieved complete response do not benefit from additional surgery or chemotherapy. 
However patients with adenocarcinoma require surgical resection. 
So, with the above evidences there is a good rationale to use combination of 
chemoirradiation and surgery and it improves survival. Definitive chemoirradiation can 
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be offered to those who are inoperable due to advanced disease or having comorbid 
conditions and patients who refuse surgery. 
With these options, the patients should understand the risks and benefits of each 
modality especially when they have options of choosing either surgery or definitive 
chemoirradiation.  
Each of it has its own advantages and disadvantages.  It is the responsibility of the 
physician to outline the risks and benefits to the patient, so that he can choose the best 
modality of treatment. 
Complications of surgery are mostly acute postoperative and the quality of life is 
effected mainly by the surgery related factors. Almost one in two (44%) of the patients 
would have had at least one major predefined complication within 30 days after surgery 
and 11 % of the operations were followed by more than two complications. The most 
frequent complications were respiratory insufficiency, severe pneumonia, anastomotic 
leakage, cardiac complications and serious infections. The factors which increased the 
risk of complications during surgery were older age, low-volume surgery, preoperative 
oncologic therapy, and a higher preoperative bleeding volume might increase the risk of 
complications, while gender and tumour stage did not play any role (37). Quality of life 
is of utmost importance as most of the patients who undergo surgery are also not cured 
(3).  
Complications associated with definitive chemoirradiation include effect on esophagus 
as well as on surrounding tissues. Esophageal complications include esophagitis, 
esophageal strictures, and fistula formation. The rate of fistula formation was around 12 
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to 17.5 % (30,38). The rates of stricture formation is 30 – 40 % in various studies and is 
increased to thrice if patient receives intraluminal brachytherapy(14,16).  Other 
complications associated with definitive chemoirradiation are pneumonitis, 
cardiotoxicity and hematological toxicities. 
The most common causes for benign strictures of esophagus are anastomotic strictures, 
radiation therapy induced strictures, photodyanamic therapy for Barrett esophagus and 
nasogastric tube injuries. The treatment for esophageal strictures consists of dilation via 
bougie or balloon, steroids injection and expandable stents.  Of all the above causes, 
radiation induced strictures are the most technicaly difficult to manage as it not only 
affects the lumen but also swallowing function due to damage of the swallowing 
muscles. These strictures are difficult to dilate and when dilatation is effective, patients 
still cannot swallow because of difficulty in swallowing coordination (39). 
 
Justification of the present study 
 
The prognosis of esophageal cancer patients is poor in spite of advancement of 
treatment techniques in fields of surgery or radiation therapy. Those patients who are 
operable at the time of diagnosis can either be treated with surgery or definitive 
radiation therapy as per the patient’s choice. It is the responsibility of the physician to 
inform the patient regarding the pros and cons of each treatment modality. As the 
survival rates are poor, one of the  main aims  of any treatment modality  is to improve 
the quality of life. Dysphagia is one such factor which decreases the quality of life in 
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esophageal cancer patients.  This study determines the incidence rate of esophageal 
stenosis after definitive radiation therapy, the risk factors causing esophageal stenosis 
and formulates an equation which predicts the incidence of stenosis before a patient 
undergoes definitive radiation therapy. This study also describes the disease response 
rates after definitive radiation therapy. 
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Materials and Methods 
 
This observational study attempts to determine the incidence and predict, the factors 
causing esophageal stenosis, in esophageal cancer patients who underwent 
chemoirradiation from January 2008 to April 2013.These patients underwent treatment 
in the Department of Radiotherapy Unit 1, Christian Medical College Hospital. All these 
patients underwent definitive radiation therapy (with external beam irradiation and 
intra luminal brachytherapy) with or without chemotherapy. 
Inclusion Criteria: 
The retrospective data includes all patients who underwent definitive irradiation with or 
without chemotherapy for esophageal cancer under Radiotherapy Unit I, from January 
2008 to February 2013. 
The prospective data included all patients who received definitive irradiation with or 
without chemotherapy for esophageal cancer from February 2013 till date. 
The data was collected after the approval from the Institutional Review Board, Christian 
Medical College, Vellore.  
Exclusion Criteria: 
Patients who did not meet the inclusion criteria. 
Evaluation: 
1. Complete clinical history and examination 
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2. Blood counts (Hemoglobin, Total count, differential counts); Serum creatinine 
and liver function tests 
3. Chest X ray 
4. Ultrasound Abdomen  
5. CT scan of the thorax 
6. Upper GI scopy 
7. Bronchoscopy (if indicated ) 
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Methodology 
 
 
 
 
 
       
       
       
       
       
       
       
       
       
   
Patients diagnosed with esophageal cancer attending the outpatient department 
of the Radiation Oncology Unit 1, Christian Medical College Vellore  
Operable/ Borderline 
operable disease  
Inoperable disease Metastatic disease/ 
Unfit for chemo-RT 
Medically fit 
for surgery 
Medically unfit 
for surgery 
Willing for 
surgery 
Not willing 
for surgery 
ASSESSMENT OF 
PATIENT FOR RISK 
FACTORS PRIOR TO 
RADICAL RADIATION 
THERAPY 
Chemotherapy/ 
Palliative approach 
RADICAL RADIATION THERAPY WITH 
OR WITHOUT CHEMOTHERAPY 
Neo-adjuvant chemo-RT 
Surgery 
ASSESSMENT OF 
STENOSIS AT 6 WEEKS,   
3 MONTHS AND AT SIX 
MONTHS ROUTINE 
FOLLOW UP VISIT 
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Details of each step : 
 
PRE TREATMENT EVALUATION 
 
 
 
 
 
 
 
ASSESSMENT OF PATIENTS PARTICIPATING IN TRAIL – AS PER THE PROFORMA 
 
DETAILS OF RADIOTHERAPY WITH OR WITHOUT CHEMOTHERAPY 
  
 
 
 
 
 
RADIATION THERAPY –CONVENTIONAL / CONFORMAL 
 45Gy in 25 fractions,180 cGy per fraction, 5 days per week, for a 
period of 5 wks  
CONCURRENT CHEMOTHERAPY –ADMINSTERED WHEN PATIENT 
FOUND FIT. 
CHEMOTHERAPEUTIC AGENTS USED: 
Cisplatin/5FU 
Cisplatin 
Paclitaxel/Carboplatin 
INFORMED CONSENT IN PROSPECTIVELY 
RECRUITED PATIENTS 
BLOOD TESTS FOR CHEMOTHERAPY, 
CHEST X-RAY 
 ULTRASOUND ABDOMEN, 
ECG, ECHO AND CARDIAC ASSESSMENT 
CT THORAX 
UPPER GI SCOPY AND BIOPSY 
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DETAILS OF HIGH DOSE RATE BRACHYTHERAPY 
 
 
 
 
DETAILS OF POST TREATMENT EVALUATION 
 
 
 
 
 
 
 
Variables used in the study 
 
There are two cohorts in the study. The first cohort is a retrospective cohort, whose 
data was already present in our records. The second is a prospective cohort, whose 
data was collected prospectively. 
2 fractions of HDR intraluminal brachytherapy 1 wk 
after completion of external RT. 
Dose : 4.5 Gy to 0.5 cm from esophageal lumen 
surface in 2 fractions.  Each fraction with 1 week 
gap 
6 WKS, 3 MONTHS AND 6 MONTHS POST 
TREATMENT ASSESSMENT 
======================== 
ULTRASOUND ABDOMEN, 
CT THORAX 
UPPER GI SCOPY 
 
43 
 
The main variables which were collected and thought to be a risk factor for the 
development of esophageal stenosis after definitive radiation therapy were 
a) Tumour stage (according to TNM classification) 
b) Wall thickness of esophagus prior to treatment 
c) Scope negotiability through the esophagus before the initiation of treatment 
d) Tumour length of esophagus 
e) Circumference of the esophageal wall involved 
 
There are no effect modifiers or confounders as all patients received definitive 
radiotherapy with or without chemotherapy as per the department protocol . 
 
END POINT ANALYSIS: 
• Incidence of esophageal stenosis  after definitive radiation therapy 
• Co-relation of esophageal stenosis with each of the variables in prediction of 
esophageal stenosis after definitive radiation therapy. 
• To formulize an equation for prediction of esophageal stenosis based on the 
identified risk factors. 
The characteristics of the patients who had already completed treatment were 
collected from the patient’s outpatient & inpatient records, radiation therapy 
treatment records, Picture Archiving and Communication System (PACS) and 
gastroscopy reports. 
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The tumour characteristics are identified based on imaging.  
a) Portion of the esophagus which was involved:  
The esophageal portion which was involved by the tumour was documented both in 
the upper GI endoscopy as well as from the CT Thorax imaging. The portion of the 
esophagus involved was divided according to the AJCC anatomical division of 
esophagus which was given in the Cancer Staging Manual, 2007. The cervical 
esophagus extends from 16 to 20 cm, i.e from cricopharyngeus muscle to thoracic inlet. 
The upper third esophagus extends from 20 to 25 cm, i.e from thoracic inlet to tracheal 
bifurcation. The middle third esophagus extends from 25 to 32 cm and lower third 
esophagus extends from 32 to 40 cm.  The anatomical regions are important in decision 
making of treatment of esophageal cancer. However, in some cases the Upper GI 
endoscope could not be negotiated beyond the growth and the entire lesion could not 
be assessed.  So as a standard for this study CT scan of the Thorax which was taken 
prior to the treatment for staging purpose was considered for measurement of length 
of the esophagus involved. Those CT scans which did not show any thickness of the 
esophageal wall, i.e those which had only ulcerative lesions were measured with upper 
GI endoscopy.  
The CT scan findings for the study were acquired with the help of one single radiologist. 
This was done to avoid any inter-observer variation in the interpretation of the CT scan 
findings. 
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b) T stage: The tumour was staged according to the AJCC 2010. It was documented 
according to the CT Thorax which was taken prior to the starting of treatment. The 
cohort was divided into two groups those with T4 stage and less than T4 stage. 
  
c) Histopathology of the tumour: The biopsy which was taken from the esophageal 
lesion during the upper GI endoscopy was reported by the Department of the 
Pathology.  
 
d) Extent of the involved circumference: This is measured from the CT scan of the 
Thorax. The circumference was divided into four equal quadrants and the number of 
quadrant involvement was documented. If the lesion was not appreciable in the CT 
scan, upper GI scopy report was taken into consideration. The patients were divided 
into those having involvement of all four quadrants (full circumference involvement) 
and those in whom 1 – 3 quadrants involved. 
 
e) Tumour length: The esophageal length which was involved by tumour was 
measured by single radiologist from the pretreatment CT scan of the thorax. In some 
cases the Upper GI endoscope could not be negotiated beyond the growth and the 
entire lesion could not be assessed.  So as a standard for this study CT scan of the 
Thorax which was taken prior to the treatment for staging purpose was considered for 
measurement of length of the esophagus involved. Those CT scans which did not show 
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any thickness of the esophageal wall, i.e those which had only ulcerative lesions were 
measured with upper GI scopy.  The patients were divided into two groups, one with 
tumours less than 8 cm and other with tumour greater than 8 cm. 
f) Wall thickness of the tumour region: This was measured from the CT scan of the 
Thorax. This was measured taking the maximum wall thickness of the esophagus of the 
tumour. The wall thickness was measured and then categorized into those which are 
less than 2 cm and those greater than 2 cm. 
 
g) Stenosis Grade before treatment: Stenosis was considered to be present if the 
scope could not be negotiated before the treatment and no stenosis if scope was 
negotiable. This data was collected from the upper GI endoscopy reports done prior to 
starting treatment. 
 
In the patients who were recruited prospectively, dysphagia was also graded  by the 
patient using a validated dysphagia rating scale. The scale used was the Modified 
O’Rourke swallowing-status staging system.  Kindly refer to [Annexure A]. 
 
Grading of stenosis after treatment 
 
 Stenosis after treatment was graded both subjectively and objectively. Subjectively it is 
measured with the modified O’Rourke swallowing status staging system. This was co-
related with the dysphagia score which the patient had prior to the treatment.  
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Objectively, the assessment of stenosis of the esophagus was based on endoscope 
negotiability. It was measured using the upper GI endoscope whose diameter is 9.2 mm. 
For this study, stenosis was defined based on the endoscope negotiability. If the scope 
was negotiable, it was considered as no stenosis and if the scope is not negotiable it is 
considered as stenotic lesion. Stenosis could be attributed to malignancy or radiation 
induced stricture. The assessment is done on all follow up visits. 
Table 1: Dysphagia Score based on Modified O’Rourke swallowing-status staging 
system 
Stage Swallowing status  
1 Asymptomatic 
2 Eats solids with some dysphagia 
3 Eats soft or pureed food only 
4 Drinks liquids only 
5 No swallowing at all 
 
Statistical Methods used for analysis of data 
Calculation of the sample size: 
In this cohort study, the expected rate of esophageal stenosis in the patients who 
received definitive radiation therapy was 50 %. Using the principle of 1 variable in a 
multivariate analysis for every 10 patients with the outcome of interest, the calculated 
sample size was 100 patients (recruited both retrospectively and prospectively). 
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The association between the esophageal stenosis after radiation therapy and each of 
the factors relating to the tumor and therapy was analyzed. The various factors which 
were analyzed were: 
a) Tumour stage (according to TNM classification) 
b) Wall thickness of esophagus prior to treatment 
c) Scope negotiable through the esophagus or not 
d) Tumour length of esophagus 
e) Circumference of the esophageal wall involvement. 
The outcome variable, stenosis, is graded according to the whether the scope is 
negotiable through the esophageal lumen before treatment and during each follow up 
visit after the treatment. In this study, the outcome was analyzed in the last follow up 
visit. 
 In consultation with the statistician, for univariate analysis, a chi-square test was 
performed to compare the distribution of the characteristics of patients and the 
treatment, among the stenosis levels. For multivariable analysis, logistic regression 
analysis was performed.  
The study population was resampled using the bootstrapping method into large 
phantom samples (bootstrap samples) using computer calculations. This method 
estimates the magnitude of fluctuations in the mean from sample to sample and gives 
an idea about the sampling distribution. The resampled cohorts were then subjected to 
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multivariate logistic regression analysis and were compared with results of the parent 
sample population. 
The β co-efficient of each variable was calculated from the odds ratio obtained for that 
variable. The β co-efficient are estimates of the odds ratio between the variable and 
outcome when the rest of the variables are held fixed. These β coefficients were utilized 
in formulizing a formula for prediction of esophageal stenosis.   
 
 
 
 
 
 
 
 
 
 
 
 
 Results 
 
Esophageal cancer patients who received definitiv
both retrospectively and prospectively in this study. 
Of these 100, 9 patients were recruited prospectively and these patients filled the 
Modified O’Rourke dysphagia questionnaire. O
patients had incomplete documentation or
end point of esophageal stenosis. Thus, we were able to assess 72 patients for the 
development of stricture after definitive 
 
Figure 1 : Study Flow chart
(Dept of Radiation Oncology, Unit I, From January 2008 to August 2013 )
75 patients  had follow up
72 patients
Assessed for the 
development of 
esophageal stricture and 
its risk factors
e radiation therapy were
Data for 100 patients was analyzed. 
f the 100 patients in this cohort, 28 
 did not come for follow up to evaluate the 
radiation therapy. 
100 esophageal cancer patients 
Received Definitive chemoirradiation
3 patients 
Had no pre-treament 
imaging or follow up 
Scopy
50 
 recruited 
 
25 patients - Lost to 
follow up
Could not be analysed
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Patient Characteristics 
There were 64 males and 36 males in the entire study group.  Of the patients who were 
analyzed in the study 45 were males and 27 were females.  
  
GRAPH FOR PATIENTS WHO HAD OUTCOME                                             
The mean age of the patients was 57.56 years. The distribution of the patients for the 
various age groups has been shown in Fig 3. 
As the histogram of the age is showing normal distribution curve, inter-quartile 
distributions were not calculated. There was no significant difference between the 
groups who had followed up and those who were lost to follow up. 
62%
38%
Sex Distribution 
Male Female
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Figure 2 : AGE DISTRIBUTION 
Table 2 shows the relative frequencies of patients according to different age groups. 
 
Table 2 : Relative frequencies of Age distribution 
Age in years Frequency Percentage Cumulative percent 
30-40 5 6.9 6.9 
40-50 9 12.5 19.4 
50-60 30 41.7 61.1 
60-70 22 30.6 91.7 
70-80 6 8.3 100 
Total 72 100  
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Tumour Characteristics  
 
The tumour characteristics which were analyzed were tumour location, tumour stage (T 
stage), tumour length, the maximum wall thickness of the esophageal growth, 
circumference of the esophageal wall involved, endoscope negotiability before 
treatment, histopathology and peri-esophageal extension. 
The particulars of the tumour characteristics are summarized in Table 3. 
Table 3 : TUMOUR CHARACTERISTICS 
 
 
Tumour Characteristics 
No of patients  
Without 
Stenosis 
With 
Stenosis 
Not 
Followed 
Up 
Total No. of 
patients 
Tumour Stage 
< T4 
T4 
 
23 
18 
 
6 
25 
 
14 
14 
 
57 
43 
Length of Esophagus 
(Involved) 
< 8 cm 
>8 cm 
 
 
35 
6 
 
 
21 
10 
 
 
24 
4 
 
 
80 
20 
Wall Thickness 
< 20 mm 
>20 mm 
 
30 
11 
 
21 
10 
 
13 
15 
 
64 
36 
54 
 
Circumference Involved (No 
of Quadrants involved) 
1 
2 
3 
4 
Could Not be assessed 
 
 
1 
2 
6 
31 
1 
 
 
0 
0 
1 
30 
0 
 
 
0 
1 
3 
23 
1 
 
 
1 
3 
10 
84 
2 
Periesophageal extension 
Present  
Absent 
 
26 
15 
 
26 
5 
 
24 
4 
 
76 
24 
Histopathology 
Well Diff Sq cell ca 
Mod. Diff Sq cell Ca 
Poor Diff Sq cell Ca 
Others 
 
4 
32 
3 
2 
 
2 
23 
6 
0 
 
4 
18 
4 
2 
 
10 
73 
13 
4 
Scope Negotiability (Before 
Rx) 
Yes 
No 
 
 
32 
9 
 
 
15 
16 
 
 
15 
13 
 
 
62 
38 
 
 
These patients who were included in the study underwent definitive radiation therapy 
with or without chemotherapy. The treatment of these patients differed in terms of 
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type of radiation received, total radiation dose, whether ILRT is given or not, if given 
what is the time gap between external beam radiation and ILRT, total duration of 
radiation and  whether concurrent chemotherapy was administered along with 
radiation therapy. Table 4 gives the detailed treatment characteristics. 
 
Table 4 : Summary of treatment Characteristics 
 
Tumour 
Characteristics 
No. of patients  
Total 
No of 
patients 
Without 
stenosis 
With stenosis No follow up 
Type of 
Radiation 
Co-60 
LINAC Radical 
(2D) 
3DCRT 
IMRT 
 
17 
7 
14 
3 
 
9 
7 
13 
2 
 
11 
5 
9 
3 
 
37 
19 
36 
8 
Radiation Dose 
(EBRT) 
< 50 Gy 
>50 Gy 
 
 
40 
1 
 
 
31 
0 
 
 
28 
0 
 
 
99 
1 
56 
 
ILRT Dose 
NIL 
4.5 Gy x 1 # 
4.5 Gy x 2 # 
 
1 
3 
37 
 
2 
0 
29 
 
1 
1 
26 
 
4 
4 
92 
Duration of RT 
<50 days 
>50 days 
 
22 
19 
 
12 
19 
 
13 
15 
 
47 
53 
Time Between 
EBRT and ILRT 
< 7 days 
>7 days 
Did not receive 
ILRT 
 
 
9 
30 
2 
 
 
7 
22 
20 
 
 
8 
20 
0 
 
 
24 
72 
4 
Concurrent 
Chemotherapy 
Given 
Not given 
 
 
32 
9 
 
 
21 
10 
 
 
23 
5 
 
 
76 
24 
 
These patients had a median follow up period of six months (range: 3 to 56 months). 
These patients were assessed for tumour response and esophageal stenosis following 
definitive radiation therapy with or without chemotherapy. The total number patients 
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who came for follow up and were included in the analysis were 72 patients. Table 5 
shows the follow up data of the patients following treatment. 
 
Table 5: FOLLOW UP DATA OF PATIENTS 
Number of Patients who were analyzed 
Who came for follow up Lost to follow up or not analyzed Total 
Number Percent Number Percent  
72 72% 28 28% 100 
 
The characteristics of patients who did not come for follow up were compared with the 
patients who came for follow up and were found to have no significant variation among 
the variables. 
 
Characteristics 
No of patients  
Came for Follow up Did not come for 
follow up 
 P value 
Staging 
T4 
< T4 
 
 
 
43 
29 
 
14 
14 
 
0.378 
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Scope negotiability 
before treatment 
Yes 
No 
 
 
47 
25 
 
 
15 
13 
 
 
0.279 
 
 
 
Length of the 
esophagus 
< 5 cm 
5-10 cm  
>10 cm  
 
 
 
14 
45 
13 
 
 
 
1 
23 
4 
 
 
 
0.095 
Wall thickness 
<10 mm 
10-20 mm 
>20 mm 
 
3 
48 
21 
 
1 
12 
15 
 
 
P = 0.072 
 
As the variables in the two groups did not differ statistically, we could interpret the 
results obtained in this study without any bias. 
Evaluation of stenotic rates  
 
These 72 patients were objectively assessed for esophageal stenosis during their follow 
up periods. 31 patients (43 %) had stenosis of esophagus following definitive radiation 
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therapy with or without chemotherapy and 41 patients (57%) had no stenosis. Table 4 
shows the stenotic rates in the followed up patients. 
 
 
 
 
Of these 31 patients who had stenosis, 12 patients had complete response, 17 patients 
had partial response or residual disease and 2 patients’ data could not be analyzed. Of 
the 41 patients who had no stenosis after definitive radiation, 23 patients had complete 
response, 17 patients had partial response and one patient had progressive disease. 
31 patients 
(43 %)
41 patients
(57%)
Esophageal stenosis in patients who had come 
for follow up
With Stenosis
Without Stenosis
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So, the incidence of stricture formation after definitive radiation was 43 % in this study 
and the incidence in patients who had complete response after definitive irradiation 
was 34 % among the stenotic group of patients. 
Each of the patient, tumour and treatment related factors were co-related with the 
outcome of esophageal stenosis following definitive radiation therapy. In the univariate 
analysis, there was significant differences showed with tumour stage, stenosis level 
before treatment and circumference of the esophageal wall involved ( p <0.05).  The 
tumour length greater than 8 cm showed a trend towards stenosis, however it was not 
statistically significant.   Significant associations were not seen with age, gender, wall 
thickness, histopathology, radiation total dose, total duration of radiation, time gap 
between external beam irradiation and ILRT, type of radiation received and concurrent 
chemotherapy. 
Association of stenosis with Scope negotiation prior to the treatment 
The present study had shown that if scope could not be passed prior to the treatment 
there is a high risk of stenosis after definitive radiation therapy. In the present study, the 
size of scope was 9.2 mm in diameter. This study shows statistically significant 
difference (p=0.009) in incidence of stenosis in patients who had esophageal lumen less 
than 9 mm in diameter prior to definitive radiation therapy. Table 6 shows the cross 
tabulation of the stenosis of esophagus prior to treatment and its complication after 
treatment. 
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   Table 6: Association of Scope Negotiation with Stricture formation 
 
 
OUTCOME 
Total NO 
STENOSIS STENOSIS 
SCOPENEG NEGOTIABLE Count 32 15 47 
% within 
OUTCOME 78.0% 48.4% 65.3% 
NOT 
NEGOTIABLE 
Count 9 16 25 
% within 
OUTCOME 22.0% 51.6% 34.7% 
Total Count 41 31 72 
% within 
OUTCOME 100.0% 100.0% 100.0% 
 
Chi-Square Tests 
 Value df Asymp.Sig (2-sided) 
Pearson Chi- Square 6.852 1 0.009 
 
Association of Tumour stage with stricture formation after definitive 
radiation therapy 
The present study initially categorized patients into early esophageal (T1 and T2 stage) 
and late esophageal cancer (T3 and T4 stage). When this was analysed there was no 
statistically difference in the stenotic outcomes (p=0.225). These patients were 
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reclassified to those having stage T4 and those having stage less than T4. When these 
two groups were analyzed, there was higher stricture formation rates in stage T4, which 
was statistically significant (p= 0.002) when compared with the patients with less than 
stage T4 disease.  
Table 7 shows the association of Tumour stage with Stricture formation 
Table 7 : Stricture formation vs Tumour Stage 
 
 
OUTCOME 
Total NO STENOSIS STENOSIS 
STAGING T4 Count 18 25 43 
% within 
OUTCOME 
43.9% 80.6% 59.7% 
<T4 Count 23 6 29 
% within 
OUTCOME 
56.1% 19.4% 40.3% 
Total Count 41 31 72 
% within 
OUTCOME 
100.0% 100.0% 100.0% 
 
Chi-Square tests 
 Value df Asymp.Sig (2-sided) 
Pearson Chi- Square 9.907 1 0.002 
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Association of Circumference of the esophageal wall involved and stricture 
formation after definitive radiation therapy 
The esophageal wall was divided into four equal quadrants. The study categorized 
patients into those who had the tumour involving all the quadrants and those who had 
involvement of less than whole of the circumference. The relation between the 
circumference of esophageal wall involvement by the tumour and occurrence of 
esophageal stenosis after definitive radiation therapy was analysed and was found to be 
statistically significant (p=0.013).  
Table 8 shows the association between the circumference of the esophageal wall 
involved by the tumour and formation of esophageal stenosis  
Table 8 : Stenosis formation vs Circumference of the esophageal wall involved 
 
 
OUTCOME 
Total 
NO 
STENOSIS STENOSIS 
CIRCUMFERENCE 1-3 
QUADRANTS 
INVOLVED 
Count 11 1 11 
% within 
OUTCOME 
24.39% 3.23% 15.28% 
ALL 4 QUADRANTS 
INVOLVED 
Count 31 30 61 
% within 
OUTCOME 
75.61% 96.77% 84.72% 
Total Count 41 31 72 
% within 
OUTCOME 
100.0% 100.0% 100.0% 
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Chi-Square tests 
 Value df Asymp.Sig (2-sided) 
Pearson Chi- Square 6.1090 1 0.013 
 
Association of esophageal stenosis and length of the esophageal wall involved 
The patients were categorized into those having less than 8 cm of the tumour length 
and those having greater than 8 cm length. This was taken from the CROSS study which 
showed that preoperative chemoirradiation had better results than surgery alone, 
included the patients with tumours less than 8 cm. The present study had shown 
increased rates of stenosis with patients having tumour length greater than 8 cm, 
however it was not statistically significant  (p=0.075). Table 8 shows the cross tabulation 
of the esophageal stenosis and tumour length (greater or lesser than 8 cm). 
   Table 8: Association of Tumour length with Stricture formation 
 
 
OUTCOME 
Total NO STENOSIS STENOSIS 
TUMOUR 
LENGTH  
 8 CM Count 35 21 56 
% within 
OUTCOME 
85.37% 67.74% 77.8% 
< 8 CM Count 6 10 16 
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% within 
OUTCOME 
14.63% 32.26% 22.22% 
Total Count 41 31 72 
% within 
OUTCOME 
100.0% 100.0% 100.0% 
 
Chi-Square Tests 
 Value Df Asymp.Sig (2-sided) 
Pearson Chi- Square 3.1723 1 0.075 
 
 
Association between wall thickness and esophageal stenosis 
The thickness of the esophageal wall involved by the tumour was classified into 
thickness of of the wall greater than 2 cm and less than 2 cm. The study did not find any 
statistical significant difference in the incidence of esophageal stenosis after definitve 
radiation therapy based on wall thickess involved by the tumour (p=0.616).   
   Table 9: Association between esophageal wall thickness and esophageal stenosis 
 
 
OUTCOME 
Total NO STENOSIS STENOSIS 
WALL 
THICKNESS 
 2 CM Count 11 10 21 
% within OUTCOME 26.83% 32.26% 29.17% 
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 < 2 CM Count 30 21 51 
% within OUTCOME                     
73.17% 
67.74% 70.83% 
Total Count 41 31 72 
% within OUTCOME 100.0% 100.0% 100.0% 
 
Chi-Square Tests 
 Value df Asymp.Sig (2-sided) 
Pearson Chi- Square 0.2518 1 0.616 
 
Other factors did not show any co-relation with the stricture formation after definitive 
radiation.  Table 10 shows the factors and their correlation with stricture formation. 
Table 10 : Correlation of other factors with stricture formation 
 
Characteristics 
 
Variables used in the Study 
 
‘p’  value 
Periesophageal 
Extension 
Present or Absent 0.139 
Type of RT Co-60, Linac Radical, 3DCRT, IMRT 0.721 
Total Duration of RT < 50 days or > 50 days 0.208 
Interval B/w EBRT 
and ILRT 
< 7 days, 7 or more days 0.954 
Concurrent 
Chemotherapy 
Yes or No 0.326 
Histopathology WDSCC, MDSCC, PDSCC and others 0.496 
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In the univariate analysis, the factors which had significant risk for the formation of 
esophageal stenosis following definitive radiation therapy were T4 stage tumours, scope 
not negotiable before initiation of treatment and tumour involving of all four quadrants 
of the esophageal wall. Tumours which were greater than 8 cm in length showed a trend 
towards increased risk of stenosis, however not statistically significant. 
 
Multivariate analysis of various risk factors for development of 
Esophageal stricture formation after Definitive radiation therapy 
 
As the sample size was only 100 with follow up patients of 72, multivariate analysis was 
done for 5 variables only.  
Table 11 below shows the Multivariate analysis of the factors which were assessed for 
stricture formation after definitive irradiation. 
Table 11: Multivariate analysis assessing the causative factors for stricture formation 
after Definitive irradiation 
 
 
Variables 
 
Univariate 
 
Multivariate 
 
OR 
 
95% C.I 
 
p 
 
OR 
 
95% C.I 
 
P 
Staging 
T4 
<T4  (Ref) 
 
2.31 
 
 
1.34 – 3.97 
 
 
0.002 
 
1.88 
 
1.05- 3.37 
 
0.03 
Scope negotiability 
Negotiable 
Not negotiable (Ref) 
 
 
0.51 
 
 
0.31 – 0.86 
 
0.01 
 
0.62 
 
0.36 – 1.08 
 
0.09 
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Tumour Length 
<8cm  (Ref) 
>8cm 
 
2.78 
 
0.88 – 8.75 
 
0.08 
 
1.70 
 
0.42-6.88 
 
0.45 
Wall thick 
<20mm  (Ref) 
>20mm 
 
1.29 
 
0.47 – 3.61 
 
0.62 
 
0.09 
 
0.26 – 3.11 
 
0.88 
Circumference 
1-3 (Ref) 
4 
 
9.68 
 
1.17 – 80.30 
 
0.01 
 
1.65 
 
0.57 – 47.58 
 
0.15 
 
After multivariate logistic regression analysis, the factor which was significant was only 
Tumour stage 4. Scope negotiability showed a trend towards the formation of 
esophageal stenosis but was not statistically significant. Rest of the variables like length 
of the tumour, wall thickness and circumference of esophageal wall involvement had 
lost its significance in multivariate analysis.  
The ‘Goodness of Fit’ for multivariate analysis was 0.70 which was not statistically 
significant and it suggests that the results were valid. 
Tumour response at the time of last follow up 
 
The median follow up period in these patients was 6 months (Range 3 – 56 months). The 
tumour response was evaluated in these patients either by CT scan of the Thorax or 
Upper GI endoscopy and biopsy if a suspicious lesion was present. 
Out of the 72 patients who came for follow up visit, 35 patients had complete response 
in their first follow up period, 34 patients had partial response, 1 patient had progressed 
and 2 patients could not be analyzed. Figure 3 shows the graphical representation of 
disease follow up of the patients who came for first follow up. 
  
Figure 3 : Tumour response 
 
Out of the 35 patients who had complete response, 12 
definitive radiation therapy 
who had residual disease, 17 patients had stricture and 17 patients had no stricture at 
the time of first follow up. The patient who had pr
liver metastases at the time of first follow up. Two patients whose disease status could 
not be evaluated had stricture formation. Table 
formation after definitive 
shows the correlation of esophageal stenosis with the outcomes of entire cohort, i.e
those who came for follow up as well as those who did not.
 
 
47%
at last follow up visit 
patients had stricture after 
and 23 patients had no stricture formation. In 34 patients 
ogression had no stricture and he had 
12 shows the incidence of stricture 
radiation therapy in patients with CR, PR and PD.
  
49%
1% 3%
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 Table 13 
. 
Complete Response
Partial Response
Progressive Disease
Not Evaluated
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Table 12: Correlational data of Stenosis rates after Definitive radiation and tumour 
Response at the time of Follow up 
 
 
Tumour response at follow up Total 
CR PR PD NA 
OUTCOME 
NO STENOSIS 
 23 17 1 0 41 
 56.1% 41.5% 2.4% 0.0% 100.0% 
STENOSIS 
 12 17 0 2 31 
 38.7% 54.8% 0.0% 6.5% 100.0% 
Total 
 35 34 1 2 72 
 48.6% 47.2% 1.3% 2.6% 100.0% 
 
CR – Complete Response, PR- Partial response, PD – Progressive Disease, NA –Could not be 
assessed 
Table 13 : Corelational data of stenosis rates after definitive RT with response rates of 
entire cohort 
 
 DiseaseFollowup Total 
CR PR PD NF 
OUTCOME 
NO STENOSIS 
Count 23 17 1 0 41 
% within OUTCOME 56.1% 41.5% 2.4% 0.0% 100.0% 
% within 
DiseaseFollowup 
65.7% 45.9% 33.3% 0.0% 41.0% 
STENOSIS 
Count 12 17 0 2 31 
% within OUTCOME 38.7% 54.8% 0.0% 6.5% 100.0% 
% within 
DiseaseFollowup 
34.3% 45.9% 0.0% 8.0% 31.0% 
NOT FOLLOW 
UP 
Count 0 3 2 23 28 
% within OUTCOME 0.0% 10.7% 7.1% 82.1% 100.0% 
% within 
DiseaseFollowup 
0.0% 8.1% 66.7% 92.0% 28.0% 
Total 
Count 35 37 3 25 100 
% within OUTCOME 35.0% 37.0% 3.0% 25.0% 100.0% 
% within 
DiseaseFollowup 
100.0% 100.0% 100.0% 100.0% 100.0% 
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Operability status and esophageal stenosis rates 
 
27 out of the 100 patients were considered operable at the time of initiation of 
radiation in the multidisciplinary tumour board meeting.  These patients however were 
not operated based on various reasons. 37 % of the patients (10 patients out of 27) who 
were operable developed stricture after radiation therapy. 11 patients had complete 
response after definitive irradiation. Out of the persons who were operable and had 
stenosis, 4 patients had complete response after definitive radiation therapy.  Three 
patients refused surgery and 1 patient was not operated in view of advanced age (68 
years).   
Table 14 shows the operability status of patients at time of starting radiation therapy. 
Table 14: Operability Status of patients at the time of Initiation of Radiation therapy 
 
 Operability Total 
OPERABLE INOPERABLE 
OUTCOME 
NO STENOSIS 
Count 11 30 41 
% within Operability 40.7% 41.1% 41.0% 
STENOSIS 
Count 10 21 31 
% within Operability 37.0% 28.8% 31.0% 
NOT FOLLOW UP 
Count 6 22 28 
% within Operability 22.2% 30.1% 28.0% 
Total 
Count 27 73 100 
% within Operability 100.0% 100.0% 100.0% 
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Table 15 shows the operability status of the patients in relation to disease outcome. 
Table 15: Operability in relation Disease Response after Definitive irradiation 
 Operability Total 
OPERABLE INOPERABLE 
DiseaseFollowup 
CR 
Count 11 24 35 
% within Operability 40.7% 32.9% 35.0% 
PR 
Count 9 28 37 
% within Operability 33.3% 38.4% 37.0% 
PD 
Count 0 3 3 
% within Operability 0.0% 4.1% 3.0% 
NF 
Count 7 18 25 
% within Operability 25.9% 24.7% 25.0% 
Total 
Count 27 73 100 
% within Operability 100.0% 100.0% 100.0% 
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Prediction formula for esophageal stenosis 
 
The second aim of the study is to formulize an equation for prediction of esophageal 
stenosis prior to initiation of definitive radiation therapy.  This was done using the odds 
ratios obtained from the multivariate analysis and the β coefficients were calculated 
using the formula:  . 
Table 17 shows the odds ratios obtained from the multivariate analysis and the 
corresponding β coefficients. 
 
Table 16: Odds Ratios and corresponding β coefficients 
Variable Odds Ratio (OR) β coefficients  (	
 
Staging 1.8881 0.6356 
Scope Negotiation 0.6266 - 0.4674 
Tumour Length 1.0705 0.5340 
Wall thickness 0.9079 - 0.9655 
Circumference Involved 5.1840 1.6455 
Constant  -4.1435 
 
The prediction equation is formulated using the constant obtained and the 
corresponding β coefficients which were obtained from the odds ratios. 
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Prediction equation: 
 
Prediction equation = y
y
e
e
+1   , where  
 
 = -4.1435+0.6356*staging-0.4674*scopnego+0.5340*length-
0.0965*wallthick + 1.6455*circumference 
 
 
e
y
 is the exponential function with a rate of change proportional to the function itself is 
expressible in terms of the exponential function; where e is the number also called as 
Napier's Number and its approximate value is 2.718281828. y is the power value of the 
exponent e. Based on the exponent e value 2.718281828 and raised to the power of y it 
has its own derivative. 
The variables like staging, scope negotiability, length, wallthickness and circumference 
were given by the numbers assigned to them during the calculations of odds ratios. 
For staging:  0– T1 to T3 stage 
                      2 – T4 stage 
For Scopenegotiability:  2 – Scope negotiable prior to starting treatment 
                                           0 – Scope not negotiable prior to treatment 
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For Length: 1 – If tumour less than or equal to 8 cm length 
                      2 – If tumour more than 8 cm length 
For Wall Thickness: 1 – If wall thickness less than or equal to 20 mm 
                                  2 – if wall thickness greater than 20 mm 
For Circumference: 1 – 1 to 3 quadrants involved 
                                    2 – 4 quadrants are involved 
After substituting the variables in the equation, the resultant value will be between 0 
and 1.  
If the value is 0.50 or less the likelihood of formation of stenosis is less and if the value is 
between 0.5 and 1, there is high chance of stenosis formation after definitive radiation 
therapy and value closer to 1 suggests a stronger co-relation. 
This formula was derived based on the derivative cohort. However this formula needs to 
tested on the validation cohort when we have a sufficient larger sample. 
Bootstrapping method for validation of the results 
 
Bootstrapping is a novel technique which resamples the parent cohort multiple times 
and tests the validation of the results obtained from the multivariate analysis. Each of 
the variables tested in multivariate analysis was sampled and the validation test was 
repeated nearly 1000 times and results were obtained. Table 16 shows the 
bootstrapping statistics 
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After doing the bootstrapping, the tumour stage 4 and involvement of entire 
circumference of the esophageal wall prior to the starting of treatment were considered 
statistically significant.  
As the bootstrapping analysis showed that T4  and involvement of all four quadrants of 
the esophageal wall prior to initiation of treatment resulted in esophageal stenosis 
which are similar variables which came as significant in univariate analysis, it suggests 
that the sample is uniform and the results are validated. The multivariate analysis 
showed that only T4 as significant in prediction of stenois, it remained statistically 
significant in bootstrapping method. 
Table 17: Bootstrapping statistics ( n=1000)  
 
Variable 
 
 
Odds Ratio 
 
Std. Err. 
 
Conf. Interval 
 
Staging (T4, <T4) 
 
 
1.90 
 
0364 
 
1.0 – 3.68 
 
Scope 
negotiability 
Yes or No prior to 
RT 
 
 
0.62 
 
 
0.354 
 
 
0.32 -1.24 
 
Tumour length 
(< 8 cm or > 8 cm) 
 
1.70 
 
1.443 
 
0.32 -10.79 
 
Wall thickness 
(<20 mm, >20 
mm) 
 
0.90 
 
1.369 
 
0.17 -3.88 
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Circumference 
involved (4 
quadrants, 1-3) 
 
5.18 
 
0.777 
 
1.64 – 19.31 
Dysphagia scores before and after definitive radiation therapy 
 
The prospective cohort had 9 patients in whom the dysphagia scores were assessed 
based on their swallowing symptoms as mentioned in Annexure A. Using the prediction 
equation which was derived from the derivative cohort an attempt is made to predict 
the stenosis rates in the prospective group of patients. Table 18 shows the dysphagia 
scores before and after treatment as well as predictive values based on the risk factors 
in these patients. 
Table 18 : Dysphagia scores before and after RT 
S. 
No 
Tumour 
Stage 
Scope 
Negotiability 
Tumour 
length 
Wall 
thickness 
 
Circumference 
Dysphagia 
Score 
before RT 
Dysphagia 
Score after 
RT 
Stenosis 
after RT 
Predicted 
Value 
1 T4 No >8 cm < 20 mm 4 3 
3 
(Remained 
Same) 
Stenosis 0.80 
2 T4 Yes >8 cm >20 mm 4 3 
2 
(Improved) 
Stenosis 0.59 
3 <T4 No <8 cm >20 mm 4 4 
3 
(Improved) 
No 
Stenosis 
0.37 
4 T4 No >8 cm >20 mm 4 4 
5 
(Worsened) 
Stenosis 0.78 
5 <T4 Yes <8 cm <20mm 3 4 
3 
(Improved) 
No 
stenosis 
0.04 
6 T4 Yes >8 cm >20mm 4 2 
3 
(Worsened) 
Stenosis 0.59 
7 <T4 Yes <8 cm <20mm 4 3 
3 
(Remained 
Same) 
Scopy 
not done 
0.40 
8 T4 Yes <8 cm <20mm 4 4 
3 
(Improved) 
No 
stenosis 
0.48 
9 T4 No <8 cm >20mm 4 4 
4 
(Remained 
Same) 
Sopy not 
done 
0.68 
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Figure 4: Comparision of Dysphagia scores before and after RT 
 
Out of the nine patients who were assessed prospectively four patients had improved 
symptoms at the time of first follow up, 2 patients worsened and 3 patients had the 
same scores. All patients who had improved dysphagia score had scope negotiability 
prior to starting radiation therapy. The patients in whom the dysphagia worsened had 
all the risk factors present, like tumour greater than 8 cm, T4 stage, whole 
circumference involvement, > 20 mm wall thickness. The patients’ who had worsening 
of dysphagia following definitive radiation therapy had stenosis of esophagus too. 
By using the prediction formula, the prediction of the esophageal stenosis following 
definitive radiation therapy was made which was correlating with the actual outcomes.  
3 3
4 4 4
2
3
4 4
3
2
3
5
3 3 3 3
4
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9
Dysphagia Score prior to RT Dysphagia Score in the first follow up
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Discussion 
 
Esophageal cancer has a poor prognosis with five year survival rates of less than 50 % 
except in stage I disease. In last three decades, there has been a shift from single 
modality of treatment towards a multi-modality approach. RTOG 85-01 was a landmark 
trial which showed that definitive chemoirradiation had similar outcomes as surgery 
alone. RTOG 92-07 study reported that addition of ILRT after external beam radiation 
had improved local control but with increase late complications like strictures and fistula 
formation. In the present era, various trials have shown that neoadjuvant 
chemoirradiation followed by surgical resection have improved overall survival(27).  
However, in inoperable esophageal cancer, definitive chemoirradiation is one of the 
modality of treatment in suitable patients. At present, the survival rates of esophageal 
cancer are low and it is important to improve the quality of life of the patient. The pros 
and cons of each of treatment modality have to be known in order to provide a better 
quality of life for the patient. This study addressed the incidence rate and factors 
affecting the formation of strictures following definitive radiotherapy with or without 
concurrent chemotherapy. 
In the present study, we had 100 patients who underwent definitive radiotherapy with 
or without concurrent chemotherapy. The study showed a higher incidence of 
esophageal cancer   in males with a male to female ratio of 3:2. Similar male 
preponderance was shown in a study from a tertiary care centre in Tamil 
Nadu(40).According to the data from GLOBOCAN 2008, the male to female ratio for 
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esophageal cancer  was 3-5:1. The mean age group of these patients was 57.6 years 
which was similar to the global population. Majority of the study population had 
squamous cell carcinoma. A study from Tamil Nadu showed a higher incidence of 
squamous cell carcinoma in patients who are above 40 years. The incidence rates of 
esophageal cancer and sex ratio distributions in the study may not be representative of 
the local population because patients from various parts of the country and from 
neighboring countries come for treatment in our institution, as tertiary care centre. 
The incidence of stenosis in patients who came for follow up was 43 % (31 patients out 
of 72 patients). Even though 28 patients were lost to follow up, the variables studied for 
analysis were comparable between the two groups (those who came for follow up and 
those who were lost to follow up). There was no significant difference in the variables 
between the two groups.  In RTOG 92-07, which reported the toxicity of combining the 
high dose rate brachytherapy with external beam irradiation in esophageal cancer, the 
incidence of stricture formation was 10 %.  A study from India reported stricture rates of 
23 % with HDR brachytherapy and external beam irradiation. Other studies which 
assessed the stricture rates showed the incidence of esophageal stenosis to be 20 – 30 
% (14–16). Study conducted by Khurana et al reported the incidence of esophageal 
stenosis was increased therefore when given ILRT boost as compared to patients who 
received external beam radiation alone.  The present study has shown a higher 
incidence of esophageal stenosis as compared with other studies which might be 
attributed to ILRT given along with external beam irradiation.  But since this study did 
not have a comparable group with external beam irradiation alone the higher incidence 
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of esophageal stenosis cannot be attributed to ILRT alone. Another reason for the higher 
incidence of esophageal stenosis could be the method used to describe esophageal 
stenosis. There is no standard method for assessing post radiotherapy esophageal 
stenosis. Atsumi et al have compared the esophageal lumen width before and after 
definitive chemoirradiation with barium swallow. 
 In the present study, we objectively defined the esophageal stenosis with relation to 
scope negotiability. Dysphagia corresponds  to the caliber of the stenosis; dysphagia to 
solids is usually present when the esophageal lumen is narrowed to 15 mm or less (3).  
The gastroscope used for all patients had a diameter of 9 mm thickness. We have 
assumed that if the scope is negotiable during the endoscopy, it was taken to be as ‘no 
stenosis’ and if not negotiable, it was considered to be ‘ stenosis’.  
This study compared 14 variables to see if they were associated with the incidence of 
esophageal stenosis following definitive radiotherapy. Of the 14 variables which were 
analyzed , only 3 variables had a statistically significant correlation with the 
development of esophageal stenosis in the univariate analysis. These were T4 stage of 
the esophageal cancer (p=0.002), non negotiability of the gastroscope prior to the 
initiation of the treatment (p=0.01) and involvement of whole circumference of 
esophagus (p=0.04).  Atsumi et al and Khurana et al have also described these variables 
to have a significant correlation with stenosis formation after definitive radiation. In 
Atsumi et al’s study, other variables like tumour length and wall thickness also showed a 
trend towards development of esophageal stenosis. In this study, tumour length more 
that 8 cm in length showed a trend towards formation of esophageal stenosis but was 
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not statistically significant ( p = 0.08).  When multivariate analysis was performed only 
T4 tumour turned out to be statistically significant. Scope non-negotiability prior to the 
treatment showed a trend towards increased risk of stenosis following definitive 
radiotherapy. This might be due to the less number of patients and the less number of 
events which occurred. 
The categorization of the variables into various groups was based on publications 
looking at similar outcomes, however with slight modifications. When T stage was 
categorized into early (includes T1 and T2 tumours) and late (T3 and T4 tumours), there 
was no significant difference in the formation of stenosis.However, when the T stage 
was categorized into T4 and less than T4 stage tumours, it showed a statistically 
significant trend in stenosis formation. Although we know T4 stage indicates poor 
prognosis with low chance of a cure, the quality of life after radiation therapy would 
remain low even after treatment with definitive radiotherapy if dysphagia persists. 
Similarly, tumour length was categorized as those less than 5 cm , 5- 10 cm and greater 
than 10 cm which did not give any statistically significance, but when this categorization 
was replaced with tumour length greater than 8 cm and less than 8 cm, it showed a 
significant trend in the formation of esophageal stenosis in the earlier group.  Larger 
trials which include more number of patients might have more events and therefore 
better validation of our prediction of dysphagia. Earlier trials which compared the 
complication rates with and without ILRT in patients receiving definitive radiation 
showed a significant increase of late complications like fistulas and strictures. We could 
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not study the effect of ILRT as almost all our patients received ILRT. The overall 
treatment time, gap between the initiation of ILRT after completion of EBRT did not 
show any statistically significance in the stenosis formation.  
The factors which were statistically significant were validated using the bootstrapping 
method. This validation test showed similar outcomes as in the multivariate analysis. 
This method has strengthened the correlation of the variables with formation of 
stenosis after definitive radiation therapy.   
The β coefficients were calculated using the odds ratios obtained for the each of the 
variables and were used in formulizing an equation for prediction of esophageal stenosis 
following radiation therapy. This would help in predicting the chance of the esophageal 
stenosis formation following definitive radiation therapy. This prediction formula 
accurately predicted the outcomes when tested on the prospective cohort of patients in 
this study. This had shown that the formula can be used for prediction of the stenosis 
following definitive radiotherapy. However, this formula was based on derivative cohort 
and needs to be tested on a larger sample to validate the equation. 
Therefore, T4 stage, non-negotiability of the endoscope prior to the radiation therapy, 
and involvement of all quadrants of the esophageal lumen are high risk factors for the 
development of stenosis following definitive radiation therapy. Patients who are 
operable but are refusing surgery can therefore be counseled to undergo surgery if they 
are at a high risk for developing stenosis if they opt to undergo radiation. 
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Limitations of the study 
 
1. Most of the patient data analyzed in the study were of a retrospective nature.  
2. Scope negotiability was taken as an indirect parameter to assess the dysphagia in 
the retrospective group.   
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Conclusions 
 
1. The incidence of stenosis in patients who came for follow up was 43 % (31 
patients out of 72 patients). 
2. The risk factors for the formation of esophageal stenosis following definitive 
radiation are T4 stage tumours, scope not negotiable before initiation of 
treatment and tumour involving full circumference of the esophageal wall. 
3.  Tumour length greater than 8 cm showed a trend towards increased risk of 
stenosis 
4. A formula to predict esophageal stenosis was derived which needs to be validated 
on a larger data set. 
5. A prospective study with a larger number of patients in whom dysphagia is 
assessed both by patient reported dysphagia scores as well as endoscopy and 
imaging would be an ideal study to predict esophageal stenosis and to validate 
the prediction formula derived in this study. 
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                                   ANNEXURES 
 
ANNEXURE A 
 
 
Degree of dysphagia assessment by modified O’Rourke swallowing-
status staging system 
 
 
 
 
 
 
 
 
 
 
 
Stage Swallowing status  
1 Asymptomatic 
2 Eats solids with some dysphagia 
3 Eats soft or pureed food only 
4 Drinks liquids only 
5 No swallowing at all 
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      ANNEXURE B 
 
PROFORMA 
 
 
‘A study to predict stenosis in esophageal cancer patients after definitive 
radiation therapy’. 
 
Name:     Hospital No. 
 
Age:      Sex: 
 
Address: 
 
 
 
Phone No. 
 
Socioeconomic Status: 
 
Performance status (ECOG): 
 
Body Weight:     Height: 
 
BMI: 
    
Smoker / Non- Smoker 
 
Alcohol:  
 
Symptoms: 
 
1. Dysphagia score 
 
2. Heart burn 
 
3. Rugurgitation 
 
4. Chest pain 
 
5. Nausea / Vomting 
 
6. Cough 
 
7. Odynophagia 
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Dyapahagia score 
1 – Asymptomatic; 2 – Eats solids with some dysphagia; 3 – Eats soft or pureed food only; 
4 – Drinks liquids only; 5 – No swallowing at all 
 
Co-morbidities: 
 
Cardiac / Pulmonary / Renal / Hepatic / Diabetes 
 
Investigation –  
 
Gastroscopy :  
 
Location :  
 
Length of the lesion : 
                                     
 
Type of lesion : 1. Polypoid  
                            2. Ulcerative 
                            3. Stricture 
 
Circumference extent :  
 
1. <25 %      2. 25 – 50 %     3. 50 -75 %               4. >75 % 
 
 
Scope  Negotiation prior to RT :  Negotiation :  Yes /No 
 
 
Feeding Procedure :   NG tube  - Y/N 
                                      PEG       -  Y/N 
 
 
Imaging : 
 
CT / PET CT scan  
 
Location :   
 
Length of the lesion -  1. < 5  cm     2. 5 - 10 cm     3. > 8 cm 
 
Wall thickeness  -  1. < 10 mm         2.10 – 20 mm       3.  > 20 mm 
 
Periesophageal extension  
 
      Intraluminal extension 
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      Nodes  -  Y/N 
 
      Distant Metastases 
 
Stage :  
 
T                                N                              M  
 
 
Histology :  
Biopsy No : 
 
 
Treatment : 
 
Neoadjuvant chemotherapy : Y/N 
 
Type of chemotherapy  
 
Number of cycles  
 
Response to Neoadjuvant chemotherapy:   
 
Radiology report : CR    PR   SD  PD 
 
Gastroscopy  
 
 
Radiation therapy details : 
 
1. Conventional                   2. Conformal 
 
Dose  :   
 
Intraluminal Brachytherapy :  Y / N 
 
Dose 
 
Total Duration of RT   
1. 6 weeks                   2. 6-7 weeks                3. > 7 weeks 
 
 
          Time between EBRT and ILRT  
1. < 7 days                  2. > 7 days 
 
94 
 
 
Concurrent Chemotherapy :  Y /N 
 
Chemotherapy Drug : 
1. Cisplatin  + 5 FU 
2. Weekly Cisplatin 
3. Cisplatin 3 weekly  
4. Docetaxel 
5. Paclitaxel and Carboplatin 
Number of cycles 
 
Follow up after RT :  
 
 1st - 6 weeks 2nd – 3 months 3rd – 6 months 
Date    
Dysphagia 
Score   
   
Radiology     
Gastroscopy- 
Scope Negotiability 
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ANNEXURE C 
  Patient’s Information sheet  
  Christian Medical College, Vellore 
                                                       Department of Radiation therapy 
 
Study Title: A study to predict stenosis in esophageal cancer patients after definitive 
radiation therapy. 
You are being requested to participate in a study which aims to identify the risk factors 
which can predict the narrowing of food pipe after treatment with radiation therapy and 
chemotherapy. This might help us in identifying the risk factors and also in predicting 
the narrowing of the food pipe after treatment on an individual basis. This study may 
help us to select the ideal type of treatment being offered to a patient based on the risk 
factors which are present. 
What does this study do? 
In this study we will collect data from your previous records like OP charts, RT charts or 
from the clinical workstation of CMC Vellore.  
New patients who are yet to undergo treatment for esophageal cancer will be asked to 
fill up a questionnaire form related to difficulty in swallowing. 
Does this study have any side effects? 
This study collects only data of the patients from patient records ,investigations and a 
questionnaire. Therefore, there is no risk of any side effects. 
If you take part what will you have to do? 
If you agree to participate in this study, you will be given a swallowing assessment  score 
questionnaire form to be filled up before your treatment and also in the subsequent 
routine follow up visits at 6 weeks, 3 months and six months. 
All other treatments that you are already on will be continued and your regular 
treatment will not be changed during this study. No additional procedures or blood tests 
will be conducted for this study.  
 
 
Can you withdraw from this study after it starts? 
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Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your 
usual treatment at this hospital in any way. 
What will happen if you develop any study related injury? 
Since this is an observational study, there is no study related injury. 
Will you have to pay for the study?  
No 
What happens after the study is over? 
You will be advised to have regular checkups at the specified intervals as advised by 
your treating doctor. 
Will your personal details be kept confidential? 
If you participate, your reports may be made available to the researchers involved in 
this study at the Christian Medical College, Vellore. This information may include: 
• Test results (lab work, x-rays, Gastroscopy, CT or MRI scans, body scans and any other 
tests you have had) 
• Details about your treatment outcome 
 
No record bearing your name will be provided to anyone else except the investigators 
involved in this study.  You will not be identified as an individual in any report coming 
from this study. 
All data obtained from this study will be stored and may be used for future analysis 
without obtaining further consent from you.   
 
If you have any further questions, please ask Dr. Venkata Krishna Reddy , Ph No : 
09751875557 , email: drkrishna@cmcvellore.ac.in 
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ANNEXURE D 
               INFORMED CONSENT 
 
Study Title: A study to predict stenosis in esophageal cancer patients after definitive 
radiation therapy. 
Study Number: 
Participant’s name:   
Date of Birth / Age (in years): 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this study and 
have clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting my 
usual treatment or my legal rights [ ] 
I understand that the study staff and institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I 
agree to this access   [ ]  
I understand that my identity will not be revealed in any information released to third 
parties or published [ ]   
I voluntarily agree to take part in this study [ ] 
 
 
Name:                                                                                   Name of witness: 
Signature:                                                                            Relation to participant: 
Date:                                                                                     Date: 
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